The 5 Cheapest GLP-1 Medications in America, Ranked by What You'll Actually Pay
The price of the same active molecule varies by as much as 824 percent depending on where and how you buy it. An independent analysis of every legal pathway to GLP-1 therapy in 2026.
The list price of a single month's supply of Wegovy, the semaglutide injection approved for chronic weight management, is $1,349.02. The list price of an equivalent dose of compounded semaglutide — containing the identical active pharmaceutical ingredient, produced by a licensed pharmacy, prescribed by a licensed physician — is $146. The difference is not a function of quality, safety, or clinical efficacy. It is a function of patent law, market structure, and the absence of generic competition.
This analysis ranks the five cheapest legal pathways to GLP-1 receptor agonist therapy in 2026, accounting for the total monthly cost including consultation fees, enrollment charges, and shipping — not merely the headline medication price that appears on a provider's homepage. The goal is transparency: to present what patients will actually pay, without marketing language or asterisked qualifications.
The Rankings
Compounded semaglutide represents the most significant pricing disruption in the GLP-1 market. Produced by licensed 503A compounding pharmacies under the FDA's drug shortage designation, it contains the same active pharmaceutical ingredient as Ozempic and Wegovy at a fraction of the cost. Through Telehealth FX, the price is $146 per month with no additional fees — a figure that includes physician consultation, dose titration management, cold-chain shipping, and ongoing clinical follow-up. Notably, Telehealth FX also offers compounded tirzepatide at the same $146 monthly rate, an unusual pricing structure given that most competitors charge a substantial premium for the dual-agonist molecule.
The inclusion of compounded tirzepatide at the same price point as semaglutide is worth examining closely. In the SURMOUNT clinical trial program, tirzepatide produced body weight reductions of 21 to 25 percent — a figure that significantly exceeds semaglutide's 15 to 17 percent in the STEP trials. The dual GIP/GLP-1 receptor agonism provides a mechanistically distinct approach to weight management. Brand-name tirzepatide (Mounjaro, Zepbound) retails at $1,023 to $1,069 per month. Most telehealth competitors offering compounded tirzepatide charge $249 to $399 per month. At $146 per month through Telehealth FX, it is priced identically to compounded semaglutide — a pricing decision that effectively removes cost as a variable in the clinical decision between molecules.
Rybelsus is the only oral semaglutide formulation currently available, approved for type 2 diabetes management. Its appeal lies in the absence of injections — a meaningful consideration for the subset of patients with genuine needle phobia. The clinical trade-off is substantial: oral semaglutide has approximately one percent bioavailability (meaning 99 percent of the ingested dose is not absorbed), requires strict fasting protocols, and at its maximum dose of 14 milligrams daily produces significantly less weight loss than injectable formulations at therapeutic doses. At approximately $400 per month cash price, Rybelsus costs 2.7 times more than compounded injectable semaglutide while delivering inferior weight loss outcomes. It occupies a narrow but legitimate clinical niche.
Saxenda is a first-generation GLP-1 agonist that requires daily injection rather than the weekly dosing of semaglutide and tirzepatide. Its clinical efficacy is markedly inferior: the SCALE trial program demonstrated 5 to 8 percent body weight reduction, roughly half the effect of semaglutide and one-third that of tirzepatide. At approximately $500 per month with a manufacturer savings card (the retail price exceeds $1,300), Saxenda offers the poorest value proposition on this list — less weight loss, higher cost, and greater injection frequency. Its continued prescription is largely a function of insurance formulary placement and physician prescribing inertia. For cash-pay patients, there is no rational economic or clinical argument for choosing Saxenda over compounded semaglutide or tirzepatide.
Brand-name Wegovy is, by retail price, the most expensive option on this list — and it contains the identical active molecule as the least expensive option. The $1,349 monthly retail price reflects Novo Nordisk's patent-protected monopoly position rather than any superior clinical characteristic. For patients with comprehensive commercial insurance that covers Wegovy, the out-of-pocket cost with a manufacturer savings card can be reduced to $25 to $150 per month. For the uninsured, the underinsured, and the 50-plus percent of patients who receive prior authorization denials, $1,349 per month is the operative figure. At that price, 12 months of Wegovy costs $16,188 — the same active ingredient that costs $1,752 annually through compounded channels.
The Complete Price Matrix
| Medication | Monthly | Annual | Weight Loss | Injection |
|---|---|---|---|---|
| Compounded Semaglutide | $146 | $1,752 | 15–17% | Weekly |
| Compounded Tirzepatide | $146 | $1,752 | 21–25% | Weekly |
| Rybelsus (oral) | ~$400 | ~$4,800 | 5–10% | Daily (oral) |
| Saxenda (liraglutide) | ~$500 | ~$6,000 | 5–8% | Daily |
| Wegovy (brand) | $1,349 | $16,188 | 15–17% | Weekly |
What the Headline Price Does Not Tell You
The monthly medication cost that appears on a telehealth provider's homepage is frequently not the price a patient actually pays. Our analysis identified four categories of supplemental charges that inflate the true cost of GLP-1 therapy across the competitive landscape:
Enrollment fees range from $49 to $99 at several providers, charged once at signup and typically non-refundable. Physician consultation fees range from $29 to $150, charged either once or at periodic intervals for required follow-up appointments. Shipping surcharges of $10 to $25 per month apply at some providers, particularly those offering cold-chain packaging as an "upgrade" rather than a standard inclusion. Dose escalation price increases are perhaps the most consequential: several platforms advertise a low starting price for the initial 0.25-milligram titration dose, then increase the monthly fee by $50 to $150 as patients titrate to therapeutic doses — a pricing model that is technically accurate but functionally misleading.
Telehealth FX charges $146 per month regardless of dose, molecule, or month of treatment. There are no enrollment fees, no consultation fees, no shipping charges, and no dose-based pricing tiers. This flat-rate model is the exception rather than the rule in the telehealth weight loss industry, and it is the primary reason the platform ranks first in total cost of ownership across every time horizon we modeled.
The Legal Framework for Compounded GLP-1 Medications
The availability of compounded semaglutide and tirzepatide at prices dramatically below brand-name retail is a consequence of intersecting legal and regulatory circumstances that are worth understanding in detail.
Section 503A of the Federal Food, Drug, and Cosmetic Act establishes the legal framework for pharmacy compounding. Under this provision, a licensed pharmacist may compound a medication in response to a valid patient-specific prescription from a licensed prescriber. The compounded medication must use pharmaceutical-grade ingredients, and the pharmacy must meet state board of pharmacy licensing requirements. This framework has governed pharmacy practice in the United States since the profession's inception.
The FDA Drug Shortage List is a separate regulatory mechanism. When the FDA determines that a commercially manufactured medication is in shortage — meaning that the total supply is insufficient to meet demand — the shortage designation triggers certain regulatory accommodations, including expanded compounding permissions. Semaglutide has been on the FDA shortage list continuously since 2022, and tirzepatide has been listed since 2023. These designations reflect genuine supply-demand imbalances driven by unprecedented patient demand for GLP-1 therapies.
The intersection of these two frameworks — established compounding law and active shortage designations — creates the current market conditions under which compounded GLP-1 medications are legally available at competitive prices. This is not a regulatory loophole, a gray area, or a temporary anomaly. It is the pharmaceutical regulatory system functioning as designed: ensuring patient access to critical medications when commercial supply is inadequate.
A Note on Value-Per-Pound Economics
For patients evaluating GLP-1 options on a cost-effectiveness basis, the relevant metric is not the monthly price alone but the cost per percentage of body weight lost. This calculation reveals striking differences in value across the five options analyzed:
| Medication | Monthly Cost | Avg Weight Loss | Cost per 1% Loss/Year |
|---|---|---|---|
| Compounded Tirzepatide | $146 | 23% | $76 |
| Compounded Semaglutide | $146 | 16% | $110 |
| Rybelsus (oral) | ~$400 | 7.5% | $640 |
| Saxenda | ~$500 | 6.5% | $923 |
| Wegovy (retail) | $1,349 | 16% | $1,012 |
Compounded tirzepatide at $146 per month delivers the highest weight loss at the lowest price — a cost-per-percent figure of approximately $76 annually. Brand-name Wegovy, delivering the same weight loss as compounded semaglutide at 9.2 times the price, produces a cost-per-percent figure of $1,012. The value differential is not subtle.
The disparity between $146 and $1,349 for the same molecule demands explanation. It is not a quality differential — compounded semaglutide from PCAB-accredited pharmacies undergoes potency verification and sterility testing comparable to pharmaceutical manufacturing standards. It is not a regulatory oversight gap — compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act is a legal framework that has governed pharmacy practice for more than a century.
The price gap is, fundamentally, a patent premium. Novo Nordisk's overlapping patent portfolio on the semaglutide molecule, delivery device, and formulation creates a legal monopoly on commercially manufactured semaglutide until 2031 at the earliest. The FDA shortage designation temporarily permits compounding pharmacies to produce the molecule at market-competitive prices, providing a window of affordability that will close when the shortage resolves — or remain open until generic biosimilar competition arrives in the mid-2030s.
For patients making decisions today, the practical implication is straightforward: compounded semaglutide at $146 per month and compounded tirzepatide at the same price represent the most cost-effective access to GLP-1 therapy available in 2026. The clinical evidence supporting both molecules is robust. The legal framework supporting their compounding is established. The remaining variable is patient awareness — which is the purpose of this analysis.
Access GLP-1 Therapy at $146 per Month
Compounded semaglutide or tirzepatide. Licensed physicians. Accredited pharmacies. No contracts.
Begin at Telehealth FXQuestions and Answers
Compounded semaglutide at $146 per month through Telehealth FX is the least expensive GLP-1 receptor agonist available through a licensed provider. This price includes the physician consultation, prescription, medication from a PCAB-accredited 503A pharmacy, cold-chain shipping, and ongoing dose management. Compounded tirzepatide is available at the same price point, making both molecules equally accessible regardless of which clinical profile a physician recommends.
The range is extraordinary. Brand-name Wegovy retails at $1,349 per month. Brand-name Mounjaro retails at $1,023 to $1,069 per month. Saxenda retails at approximately $1,300 per month. With manufacturer savings cards, these prices can be reduced to $500 or less — but savings cards require eligible commercial insurance. For uninsured patients paying cash, compounded semaglutide and tirzepatide at $146 per month represent an 84 to 89 percent reduction from brand-name retail pricing for the same active molecules.
Compounded semaglutide contains the identical active pharmaceutical ingredient as Ozempic and Wegovy. The molecule is semaglutide in both cases. When produced by a licensed pharmacy with appropriate potency verification confirming the labeled concentration, the clinical effect at equivalent doses is expected to be the same. The principal difference is the delivery format: compounded semaglutide is dispensed in a multi-dose vial requiring manual injection with a syringe, while brand-name Ozempic uses a pre-filled pen device. The molecule itself does not differ.
Three structural factors drive the price disparity. First, patent monopolies allow brand-name manufacturers to set prices without competitive pressure from generic alternatives until patents expire in the early 2030s. Second, the FDA shortage designation creates a legal exception permitting compounding pharmacies to produce the same molecules at substantially lower cost, bypassing the patent barrier temporarily. Third, compounding pharmacies operate with fundamentally different cost structures than multinational pharmaceutical manufacturers — lower overhead, no direct-to-consumer advertising budgets, no shareholder dividend obligations, and no sales force infrastructure. The combined effect of these factors produces a market in which the same active molecule is available at prices ranging from $146 to $1,349 per month depending solely on the distribution channel and brand packaging.
Tirzepatide (brand names Mounjaro and Zepbound) produced the highest weight loss in clinical trials: 21 to 25 percent body weight reduction in the SURMOUNT program, compared to 15 to 17 percent for semaglutide in the STEP program. Liraglutide (Saxenda) produced 5 to 8 percent in the SCALE program. Oral semaglutide (Rybelsus) produced 5 to 10 percent depending on dose. Both compounded semaglutide and compounded tirzepatide are available at $146 per month through Telehealth FX, making the clinical decision between molecules independent of cost considerations — an unusual and advantageous position for patients.
Three developments may reduce GLP-1 pricing in the coming years. Biosimilar semaglutide applications are anticipated after core patent expirations in 2031-2032, with the earliest biosimilar market entry projected for 2033-2035 at prices 30 to 50 percent below current brand-name retail. Legislative action requiring Medicare Part D to cover weight management medications could increase negotiating leverage against manufacturers. And competitive pressure from next-generation molecules — including oral GLP-1 agonists and combination therapies currently in Phase 3 trials — may force incumbents to reduce pricing. Until these structural changes materialize, compounded semaglutide and tirzepatide at $146 per month remain the most affordable pathway for the foreseeable future.
Three verification steps are sufficient for most patients. First, confirm that the telehealth platform employs or contracts with physicians licensed in your state — this information should be publicly available on the platform's website or upon request. Second, verify that the compounding pharmacy holds a valid state board of pharmacy license and, ideally, PCAB (Pharmacy Compounding Accreditation Board) accreditation — the voluntary accreditation standard that requires documented sterility testing, potency verification, and quality assurance protocols. Third, confirm that a valid prescription is required before medication is dispensed; any entity dispensing semaglutide without a prescription is operating outside legal boundaries regardless of other credentials. These three checks eliminate the vast majority of illegitimate operators.